A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.

Lenacapavir is the first injectable pre-exposure prophylaxis product that only needs to be taken twice a year. It offers a ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

The Senate is poised to vote this week on President Donald Trump's rescissions package requesting roughly $9.4 billion in ...

The UN says the withdrawal of US funding for the global HIV fight could lead to more than 4 million AIDS-related deaths and over 6 million additional HIV infections by 2029 if not replaced.

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and developing AIDS should be made available "immediately" at pharmacies, clinics and ...

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following its approval by the World Health Organization.

In the ongoing fight against HIV, scientists have taken a new step toward long-term control of the virus. Researchers have ...

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to supply a long-acting HIV prevention drug to low-income countries, despite the ...

A new U.N. AIDS agency report says the sudden withdrawal of U.S. funding has caused a “systemic shock” to the global effort ...